Cidara Therapeutics Inc expected to post a loss of $4.25 a share - Earnings Preview

Cidara Therapeutics

29/10/2024 11:17

* Cidara Therapeutics Inc  CDTX.OQ   CDTX.O  is expected
to show a
fall in quarterly revenue when it reports  results on October 31
(estimated) for the period ending September 30 2024
    * The San Diego California-based  company is expected to
report a
96.6% decrease in revenue to $433.33 thousand from $12.72
million a year ago, according to the mean estimate from 3
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Cidara Therapeutics Inc
is for
a loss of $4.25 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Cidara
Therapeutics Inc is 25.00​, above​ its last closing price
of $12.47. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jan. 1 0001   -4.01       -3.22      -1.39     Beat    56.9
 Jan. 1 0001   -0.20       -0.20      -2.28     Missed  -1,040
 Jan. 1 0001               -2.07      -0.80     Beat    61.3​
 Sep. 30 2023  -3.19       -3.25      -1.80     Beat    44.6
 ​​Mar.        -2.04       -0.73      -2.80     Missed  -7.7
 31 2023                                                
 Mar. 31 2023  -0.41       -0.73      0.60      Beat    181.8​
 Jan. 1 0001   -4.24       -3.35      -3.80     Missed  -13.4
 Sep. 30 2022  3.71        3.60       3.40      Missed  -5.6
 This summary was machine generated October 29 at 11:17 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)